According to filings with the U.S. Securities and Exchange Commission, Adela, Inc. is raising up to $27,000,000.00 in new funding. The federal securities law requires the notice to be filed by companies that have sold securities without registration under the Securities Act of 1933 in an offering made under Rule 504 or 506 of Regulation D or Section 4(a)(5) of the Securities Act. A company must file this notice within 15 days after the first sale of securities in the offering. For this purpose, the date of first sale is the date on which the first investor is irrevocably contractually committed to invest. Each issuer of securities that sells its securities in reliance on an exemption provided in Regulation D or Section 4(a)(5) of the Securities Act of 1933 must file this notice containing the information requested with the U.S. Securities and Exchange Commission (SEC) and with the state(s) requiring it. If more than one issuer has sold its securities in the same transaction, all issuers should be identified in this filing with the SEC.

About Adela, Inc.
Adelas mission is to develop innovative and accessible technologies that harness biology and change the way we diagnose and treat disease. Adelas genome-wide methylation enrichment technology was originally developed by Chief Scientific Officer Dr. Daniel De Carvalho, PhD, at University Health Networks Princess Margaret Cancer Centre. Adela is initially planning to develop the technology for use across the entire cancer continuumfor detection, diagnosis and management of disease.

To learn more about Adela, Inc., visit http://www.adelabio.com/
Adela, Inc. Linkedin Page: https://www.linkedin.com/company/adela-inc/

Contact:
Lisa Alderson, Chief Executive Officer
888-210-1773
https://www.linkedin.com/in/lalderson/

SOURCE: http://www.intelligence360.io
Copyright (c) 2025 SI360 Inc. All rights reserved.